127 related articles for article (PubMed ID: 12670648)
21. Structure-based design of TACE selective inhibitors: manipulations in the S1'-S3' pocket.
Huang A; Joseph-McCarthy D; Lovering F; Sun L; Wang W; Xu W; Zhu Y; Cui J; Zhang Y; Levin JI
Bioorg Med Chem; 2007 Sep; 15(18):6170-81. PubMed ID: 17606376
[TBL] [Abstract][Full Text] [Related]
22. Protease inhibitors: synthesis of bacterial collagenase and matrix metalloproteinase inhibitors incorporating succinyl hydroxamate and iminodiacetic acid hydroxamate moieties.
Santos MA; Marques S; Gil M; Tegoni M; Scozzafava A; Supuran CT
J Enzyme Inhib Med Chem; 2003 Jun; 18(3):233-42. PubMed ID: 14506914
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket.
Yamamoto M; Tsujishita H; Hori N; Ohishi Y; Inoue S; Ikeda S; Okada Y
J Med Chem; 1998 Apr; 41(8):1209-17. PubMed ID: 9548812
[TBL] [Abstract][Full Text] [Related]
24. Protease inhibitors. Part 12. Synthesis of potent matrix metalloproteinase and bacterial collagenase inhibitors incorporating sulfonylated N-4-nitrobenzyl-beta-alanine hydroxamate moieties.
Scozzafava A; Ilies MA; Manole G; Supuran CT
Eur J Pharm Sci; 2000 Jul; 11(1):69-79. PubMed ID: 10913755
[TBL] [Abstract][Full Text] [Related]
25. N-O-Isopropyl Sulfonamido-Based Hydroxamates as Matrix Metalloproteinase Inhibitors: Hit Selection and in Vivo Antiangiogenic Activity.
Nuti E; Cantelmo AR; Gallo C; Bruno A; Bassani B; Camodeca C; Tuccinardi T; Vera L; Orlandini E; Nencetti S; Stura EA; Martinelli A; Dive V; Albini A; Rossello A
J Med Chem; 2015 Sep; 58(18):7224-40. PubMed ID: 26263024
[TBL] [Abstract][Full Text] [Related]
26. Recent advances in studies on hydroxamates as matrix metalloproteinase inhibitors: a review.
Yadav RK; Gupta SP; Sharma PK; Patil VM
Curr Med Chem; 2011; 18(11):1704-22. PubMed ID: 21428880
[TBL] [Abstract][Full Text] [Related]
27. Aryl ketones as novel replacements for the C-terminal amide bond of succinyl hydroxamate MMP inhibitors.
Sheppard GS; Florjancic AS; Giesler JR; Xu L; Guo Y; Davidsen SK; Marcotte PA; Elmore I; Albert DH; Magoc TJ; Bouska JJ; Goodfellow CL; Morgan DW; Summers JB
Bioorg Med Chem Lett; 1998 Nov; 8(22):3251-6. PubMed ID: 9873712
[TBL] [Abstract][Full Text] [Related]
28. Oxal hydroxamic acid derivatives with inhibitory activity against matrix metalloproteinases.
Krumme D; Tschesche H
Bioorg Med Chem Lett; 2002 Mar; 12(6):933-6. PubMed ID: 11958997
[TBL] [Abstract][Full Text] [Related]
29. Affinity and selectivity of matrix metalloproteinase inhibitors: a chemometrical study from the perspective of ligands and proteins.
Matter H; Schwab W
J Med Chem; 1999 Nov; 42(22):4506-23. PubMed ID: 10579815
[TBL] [Abstract][Full Text] [Related]
30. Synthesis, experimental evaluation and molecular modelling of hydroxamate derivatives as zinc metalloproteinase inhibitors.
Sjøli S; Nuti E; Camodeca C; Bilto I; Rossello A; Winberg JO; Sylte I; Adekoya OA
Eur J Med Chem; 2016 Jan; 108():141-153. PubMed ID: 26638045
[TBL] [Abstract][Full Text] [Related]
31. QSAR modelling on a series of arylsulfonamide-based hydroxamates as potent MMP-2 inhibitors.
Sanyal S; Amin SA; Adhikari N; Jha T
SAR QSAR Environ Res; 2019 Apr; 30(4):247-263. PubMed ID: 31012354
[TBL] [Abstract][Full Text] [Related]
32. Binding affinity of hydroxamate inhibitors of matrix metalloproteinase-2.
Zhang W; Hou TJ; Qiao XB; Huai S; Xu XJ
J Mol Model; 2004 Apr; 10(2):112-20. PubMed ID: 14986176
[TBL] [Abstract][Full Text] [Related]
33. The selectivity of galardin and an azasugar-based hydroxamate compound for human matrix metalloproteases and bacterial metalloproteases.
Sylte I; Dawadi R; Malla N; von Hofsten S; Nguyen TM; Solli AI; Berg E; Adekoya OA; Svineng G; Winberg JO
PLoS One; 2018; 13(8):e0200237. PubMed ID: 30075004
[TBL] [Abstract][Full Text] [Related]
34. New matrix metalloproteinase inhibitors based on γ-fluorinated α-aminocarboxylic and α-aminohydroxamic acids.
Behrends M; Wagner S; Kopka K; Schober O; Schäfers M; Kumbhar S; Waller M; Haufe G
Bioorg Med Chem; 2015 Jul; 23(13):3809-18. PubMed ID: 25921268
[TBL] [Abstract][Full Text] [Related]
35. 3D-QSAR of histone deacetylase inhibitors: hydroxamate analogues.
Juvale DC; Kulkarni VV; Deokar HS; Wagh NK; Padhye SB; Kulkarni VM
Org Biomol Chem; 2006 Aug; 4(15):2858-68. PubMed ID: 16855733
[TBL] [Abstract][Full Text] [Related]
36. N-O-isopropyl sulfonamido-based hydroxamates: kinetic characterisation of a series of MMP-12/MMP-13 dual target inhibitors.
Santamaria S; Nuti E; Cercignani G; Marinelli L; La Pietra V; Novellino E; Rossello A
Biochem Pharmacol; 2012 Sep; 84(6):813-20. PubMed ID: 22771631
[TBL] [Abstract][Full Text] [Related]
37. Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with sulfonylated hydroxamates.
Nuti E; Orlandini E; Nencetti S; Rossello A; Innocenti A; Scozzafava A; Supuran CT
Bioorg Med Chem; 2007 Mar; 15(6):2298-311. PubMed ID: 17276072
[TBL] [Abstract][Full Text] [Related]
38. Potent and selective 2-naphthylsulfonamide substituted hydroxamic acid inhibitors of matrix metalloproteinase-13.
Tommasi RA; Weiler S; McQuire LW; Rogel O; Chambers M; Clark K; Doughty J; Fang J; Ganu V; Grob J; Goldberg R; Goldstein R; Lavoie S; Kulathila R; Macchia W; Melton R; Springer C; Walker M; Zhang J; Zhu L; Shultz M
Bioorg Med Chem Lett; 2011 Nov; 21(21):6440-5. PubMed ID: 21937229
[TBL] [Abstract][Full Text] [Related]
39. Radiolabeled hydroxamate-based matrix metalloproteinase inhibitors: How chemical modifications affect pharmacokinetics and metabolic stability.
Hugenberg V; Hermann S; Galla F; Schäfers M; Wünsch B; Kolb HC; Szardenings K; Lebedev A; Walsh JC; Mocharla VP; Gangadharmath UB; Kopka K; Wagner S
Nucl Med Biol; 2016 Jul; 43(7):424-37. PubMed ID: 27179748
[TBL] [Abstract][Full Text] [Related]
40. MMP-13 selective alpha-sulfone hydroxamates: identification of selective P1' amides.
Fobian YM; Freskos JN; Barta TE; Bedell LJ; Heintz R; Kassab DJ; Kiefer JR; Mischke BV; Molyneaux JM; Mullins P; Munie GE; Becker DP
Bioorg Med Chem Lett; 2011 May; 21(10):2823-5. PubMed ID: 21493063
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
